REVIEW article
Front. Drug Saf. Regul.
Sec. Advanced Methods in Pharmacovigilance and Pharmacoepidemiology
Volume 5 - 2025 | doi: 10.3389/fdsfr.2025.1620314
Centralized Daily Drug Management in Clinical Trial Institutions and Specific Implementation Plans
Provisionally accepted
Yu Tang1
Xiaolong Fang2,3*- 1Jiangnan University, Wuxi, China
- 2Drug Clinical Trial Facility, Affiliated Hospital of Jiangnan University, Wu Xi, China
- 3Affiliated Hospital of Jiangnan University, Wu Xi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background:Experimental drug management is an important part of clinical trial management and directly relates to the reliability of clinical trial data and the safety of participants. This study explores the implementation of centralized pharmacy management in clinical drug trials, addressing the limitations of decentralized approaches. Methods: It involves the establishment of a centralized drug warehouse with unified processes and digital systems, primarily relying on the Cold Chain Cloud Platform, Service Cloud Platform, and Enterprise WeChat Platform, to enhance precision and efficiency. Results:It indicated a significant reduction in error rates and improved adherence to clinical trial protocols. The centralized model also minimized protocol deviations and strengthened participant safety. Conclusions: It highlights the benefits of centralized management in enhancing drug administration efficiency and maintaining high standards of trial conduct, suggesting future integration with Artificial Intelligence (AI) and Electronic Health Records (EHR) for more precise pharmaceutical services.
Keywords: Keyword Clinical trials, Drug management, Implementation plan, standardization, Centralized management mode
Received: 29 Apr 2025; Accepted: 09 Jun 2025.
Copyright: © 2025 Tang and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaolong Fang, Drug Clinical Trial Facility, Affiliated Hospital of Jiangnan University, Wu Xi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.